Sunshine Biopharma Q3 Loss Widens to $5.20/Share, Missing Estimates
SBFM is trading near its 52-week low of $2.53 (6.7% above the low) on light trading volume (0.2× avg).
Summary
Sunshine Biopharma posted a Q3 adjusted loss of $5.20 per share, wider than the $3.40 loss the lone analyst expected and far above last year's loss. Revenue was essentially flat at $9.44 million, just under the $9.60 million consensus, and the net loss came in at $1.22 million. The stock has already collapsed 81.6% this quarter and 98.8% year to date, so the miss lands on a name that has been in freefall. The company still had $14.6 million in cash at quarter-end, which management says covers about 29 months of operations — that cash cushion, not the P&L, is what matters here. Note the per-share figures reflect the 1-for-20 reverse split effective October 26, so the headline loss is post-split. The bigger overhang remains the Series D warrant structure that can add tens of millions of shares and reprice to $0.275 after a share combination.
At the time of this announcement, SBFM was trading at $2.70 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.2M. The 52-week trading range was $2.53 to $464.00. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Reuters.